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Growth Hormone and Cardiovascular Disease*James A. de Lemos, MD, Rebecca Vigen, MD, MSCSA nabolic hormone use is increasingly commonand includes replacement in patients withhormone deﬁciencies, questionable uses in
those with borderline-low levels, and clear abuses
among athletes aiming to gain a competitive advan-
tage. Recently, direct-to-consumer marketing touting
the beneﬁts of “low T” treatment has led to increased
testosterone use among middle-aged and older men,
despite inadequate cardiovascular safety data. Al-
though the Testosterone in Older Men Trial showed
improvements in strength among treated patients, it
was prematurely halted due to increased cardiovas-
cular events in the treatment arm (1). Additionally,
observational studies have demonstrated an associa-
tion between testosterone prescription and increased
myocardial infarction rates (2), as well as associations
between testosterone therapy and adverse cardiovas-
cular outcomes including all-cause mortality, myo-
cardial infarction, and ischemic stroke (3). Recently,
the U.S. Food and Drug Administration (FDA)
announced an investigation of the safety of testos-
terone use, emphasizing that testosterone is only
approved for use in men with low levels who have
an associated medical condition (4).
The other anabolic hormone with clear treatment
indications, as well as a potential for “indication
creep” and abuse, is growth hormone (GH). GH is only
approved for adults with proven deﬁciency, acquired
immune deﬁciency syndrome wasting syndrome, or*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.short bowel syndrome, and the Federal Food, Drug,
and Cosmetic Act prohibits GH use for off-label in-
dications. Among adults with GH deﬁciency, re-
placement improves body composition (5), exercise
performance (6), and bone density (7). Additionally,
GH replacement was shown to improve surrogate
cardiovascular disease markers, including lipids (5)
and inﬂammatory markers (8). Whether GH replace-
ment improves cardiovascular morbidity or mortality
in this population remains unknown.
Beyond these indications, athletes have used high-
dose GH for performance enhancement. Additionally,
low-dose GH in combination with other hormones,
including testosterone, has been marketed by anti-
aging clinics. Following the 1990 publication of a
small study that demonstrated improvements in body
composition among older men following GH supple-
mentation, the use of GH as an antiaging therapy
expanded rapidly and continues to increase (9,10).
Despite no projected change in the prevalence of GH
deﬁciency, the global market for GH is expected to
increase from $3.5 billion in 2011 to $4.7 billion by
2018 (11). This is not unexpected, as previous data
demonstrated that up to 30% of GH prescriptions in
the United States were prescribed for off-label in-
dications (10).
Despite high rates of unapproved GH use for per-
formance enhancement and anti-aging, there are
limited efﬁcacy data to support improvements in
physical status. Although GH administration in-
creased lean body mass in a study of healthy, young
individuals, it had no effect on strength or exercise
capacity (12). A meta-analysis evaluating GH treat-
ment in elderly individuals found improvements in
body composition, but no changes in cholesterol,
maximal rate of oxygen consumption, bone density,
or blood glucose (13). Additionally, high rates of
adverse events were noted in treatment groups,
most commonly soft tissue edema, carpal tunnel
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1462syndrome, arthralgia, and gynecomastia (13). There
are no clinical trials evaluating the long-term cardio-
vascular safety and efﬁcacy of GH therapy in healthy
individuals.SEE PAGE 1452In this issue of the Journal, Hallengren et al. (14)
report an interesting epidemiological study that may
provide additional insights into the cardiovascular
effects of GH. They measured GH with a novel high-
sensitivity (hs) assay in 4,323 healthy participants in
the Malmö Diet and Cancer study and evaluated the
associations between GH concentrations and cardio-
vascular risk factors, as well as incidence of coronary
artery disease, stroke, congestive heart failure, and
all-cause and cardiovascular mortality (14). Although
no direct comparisons with a standard GH assay were
performed, the hs-GH assay used by Hallengren et al.
(14) likely captures a full range of values below the
detection limits of standard assays, allowing the in-
vestigators to explore cardiac associations with
physiological and not pathological levels of the hor-
mone. Although individuals with higher GH levels
had more favorable body composition and lipid pro-
ﬁles, similar to observations from studies of GH
replacement (5), they also had higher rates of coro-
nary artery disease, stroke, congestive heart failure,
and all-cause and cardiovascular mortality (14). These
ﬁndings have potential implications for the use of
hs-GH as a biomarker in the general population, as
well as implications for the appropriate use of GH
in those with a diagnosed deﬁciency and for those
using GH inappropriately.
Although hs-GH levels were statistically associated
with adverse cardiovascular endpoints in the Malmö
study, the magnitude of the association was modest
and led to only a very small improvement in the
C-statistic (14). For biomarkers to be useful for risk
assessment in the general population, the magnitude
of association will need to be larger and associated
with improvements in discrimination and/or clinical
metrics of risk classiﬁcation, such as net reclassiﬁca-
tion improvement (15,16). Moreover, GH is probably
too difﬁcult to measure to be useful as a routine
biomarker. As highlighted by the authors (14), GH
secretion is pulsatile and may differ based on sleeppatterns, time of day, and food intake (17). For these
reasons, we do not believe it is likely that hs-GH will
emerge as an important biomarker for cardiovascular
risk assessment. However, well-performed biomarker
studies, such as the present one, may have thera-
peutic implications and contribute to our under-
standing of disease processes, even if the magnitude
of association of the biomarker with outcomes is
modest. In this case, the ﬁndings raise preliminary
concerns about the potential for adverse cardiovas-
cular safety with GH treatment or illicit use.
Several caveats need to be mentioned. First, the
application of the results of this analysis to the
treatment of adults and children with diagnosed GH
deﬁciency is unclear, because there may be important
differences between endogenous GH levels and GH
replacement. Indeed, the associations reported
here appear to counter those seen in studies of
GH replacement. The same difﬁculty in applying
these results to GH-deﬁcient patients exists when
we consider their application to individuals who
use exogenous GH for antiaging or performance-
enhancing purposes.
This interesting study by Hallengren et al. (14)
should be considered hypothesis-generating and
should prompt additional study of the effects of GH
on the cardiovascular system. Thus far, the data are
conﬂicting, with some studies showing protective
effects and others (including the present study) sug-
gesting potential hazards. It is imperative that the
cardiovascular safety of GH in adults at risk for or
with cardiovascular disease be determined before
the “genie gets out of the bottle” and GH use expands
even further. The current situation with testoster-
one, where cardiovascular safety concerns are now
emerging after the “genie” was released, should serve
as a cautionary tale. Additionally, patients who are
using GH for indications beyond those that are U.S.
Food and Drug Administration–approved should be
informed of the uncertainty regarding beneﬁts and
the potential for harm.
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